Jupiter Neurosciences’ $100M ALA-002 Bet Is a Regulatory Arbitrage Play, Not a Science Story
Jupiter Neurosciences (JUNS) just licensed ALA-002, a Novel Chemical Entity MDMA, for $100M+—here's why the NCE status matters more...
CNS Pipeline Strategy
BMS Just Paid to Solve Its Patent Cliff With Someone Else’s Pipeline
Bristol Myers Squibb's 13-program deal with Hengrui Pharma is the clearest signal yet that Western pharma's next growth decade...
Chinese Biotechs Shift From Building to Partnering as Deal Values Double
At BIO China, pharma executives and investors debated whether Chinese biotechs should pursue full integration or adopt partnership-led growth...
argenx’s $1.3 Billion Quarter Proves FcRn Dominance — Now the Real Test Begins
argenx hit $1.3B in Q1 2026 product sales, up 63% YoY. With two VYVGART label expansions pending and empasiprubart...
The Six-Month Shot That Broke HIV’s Business Model: Lenacapavir Is Rewriting Who Wins in a Market Everyone Thought Was Settled
Gilead's lenacapavir approval for HIV PrEP—100% efficacy, twice-yearly dosing—threatens daily-pill incumbents and signals a mechanism arms race across the...
Lilly’s $6.3B Sleep Bet Isn’t About Sleep — It’s About Owning the Next Neuroscience Platform
Eli Lilly just paid $6.3 billion upfront for Centessa Pharmaceuticals and its sleep disorder pipeline. The price looks steep...
Fortress Biotech’s $205M Voucher Sale Is the Smartest Capital Move No One Is Talking About
Fortress Biotech just converted a rare pediatric disease priority review voucher into $205 million in cash — while the...